Findings

What do systematic reviews say?

89 questions · 92 findings · 23 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 27 · 29.3%GRADE not reported 14 · 15.2%Very low 7 · 7.6%Low 17 · 18.5%Moderate 23 · 25%High 4 · 4.3%

Endoscopic vs open or mini‐open carpal tunnel release

Grip strength at 3 months or less Dynamometer · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 560 participants
Moderate

Endoscopic vs open or mini‐open carpal tunnel release

Grip strength ‐ Vitamin D · carpal tunnel syndrome

1 finding from 1 review

Endoscopic release for carpal tunnel syndrome 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 56 participants
Low

Intervention not reported

Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

Intervention not reported

Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Moderate

Neurodynamic mobilisation vs no treatment

Improvement in neurophysiological parameters at ≤ 3 months · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Strengthening exercise vs no exercise

Change in maximal isometric voluntary contraction force (Nm) · patients with people with peripheral neuropathy

1 finding from 1 review

Exercise for people with peripheral neuropathy 2004 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Moderate

Any CNTF vs placebo

Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

IVIg vs intravenous methylprednisolone

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 1.46 [0.4, 5.38]
1 study · 45 participants
Moderate

IVIg vs intravenous methylprednisolone

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

IVIg vs intravenous methylprednisolone

Change in mean disability score at 24 weeks or later · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate

IVIg vs intravenous methylprednisolone

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 4.4 [0.22, 86.78]
1 study · 45 participants
Moderate

Calf, quadriceps, and hamstring stretching vs no stretching

Cramp frequency (number of cramps in preceding week) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Calf, quadriceps, and hamstring stretching vs no stretching

Adverse events · 50‐ to 60‐year‐old women with metabolic syndrome

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Moderate

Calf, quadriceps, and hamstring stretching vs no stretching

Cramp severity (0 to 10 VAS; higher = more pain) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low